In Thailand, the eligibility criteria for anti-TNF for JIA are considered based on individual health benefit schemes and are indicated in patients with refractory disease despite treatment with combinations of NSAIDs, DMARDs, and systemic corticosteroids [7]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.